TG Therapeutics Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
244
- Stock Symbol
-
TGTX
- Investments
-
1
- Share Price
-
$15.72
- (As of Friday Closing)
TG Therapeutics General Information
Description
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Contact Information
- 3020 Carrington Mill Boulevard
- Suite 475
- Morrisville, NC 27560-5435
- United States
TG Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.72 | $16.03 | $6.46 - $35.67 | $2.43B | 151M | 5.62M | -$0.20 |
TG Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 1,226,284 | 1,625,689 | 2,386,557 | 7,005,131 |
| Revenue | 189,771 | 2,785 | 6,689 | 152 |
| EBITDA | (12,402) | (187,629) | (341,969) | (272,678) |
| Net Income | (25,906) | (198,335) | (348,101) | (279,381) |
| Total Assets | 331,067 | 193,572 | 379,629 | 625,642 |
| Total Debt | 0 | 83,060 | 79,047 | 41,976 |
TG Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TG Therapeutics Comparisons
Industry
Financing
Details
000000
00 000
TG Therapeutics Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biogen | Formerly VC-backed | Cambridge, MA | 0000 | 000 | 000000&0 | |
| 00 000000000000 | Formerly VC-backed | Durham, NC | 000 | 00000 | 00000000 | 00000 |
| 00000000 | Venture Capital-Backed | New York, NY | 00 | 00000 | 00000000000 | 00000 |
| 0000 00000000 | Formerly VC-backed | Stamford, CT | 00 | 00000 | 000000&0 | 00000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 000.00 | 000000000 | 000.00 |
TG Therapeutics Patents
TG Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220143026-A1 | Triple combination to treat b-cell malignancies | Pending | 12-Nov-2020 | 000000000 | |
| EP-3509634-A1 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers | Inactive | 09-Sep-2016 | 0000000000 | |
| CA-3035976-A1 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers | Pending | 09-Sep-2016 | 0000000000 | |
| AU-2017322501-A1 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers | Inactive | 09-Sep-2016 | 0000000000 | |
| CA-3024123-A1 | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders | Inactive | 27-May-2016 | A61K31/4985 |
TG Therapeutics Executive Team (4)
TG Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000 00 | TG Therapeutics | Board Member | 000 0000 |
| 0000000 00000000 | Self | Board Member | 000 0000 |
| 00000000 0000000 | Self | Board Member | 000 0000 |
| 0000000 00000 00 | Self | Founder, Chief Executive Officer, President & Chairman | 000 0000 |
| 00000 000000 | TG Therapeutics | Board Member | 000 0000 |
TG Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
TG Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Manhattan Pharmaceuticals | 12-Mar-2010 | 0000000000 | Pharmaceuticals |
TG Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 07, 2023
28.92 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Biotechnology
Subindustry
00 of 399
Rank
Percentile
